Catalyst Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Catalyst Pharmaceuticals generated cash of $143,600,000, which is more than the previous year. Cash used in financing activities reached the amount of -$10,857,000 last year. Net change in cash is therefore -$160,759,000.
Cash Flow
| 2014 | -12.94M | -8.74M | 28.56M |
|---|---|---|---|
| 2015 | -18.01M | -6.49K | 37.15M |
| 2016 | -17.96M | 3.55M | 68.98K |
| 2017 | -13.74M | -3.95K | 57.35M |
| 2018 | -25.70M | -15.52M | 293.11K |
| 2019 | 34.61M | 37.22M | 1.11M |
| 2020 | 45.03M | -5.01M | 701.93K |
| 2021 | 60.37M | -11.02M | -8.14M |
| 2022 | 116.04M | 9.20M | 1.69M |
| 2023 | 143.6M | -293.50M | -10.85M |
CPRX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 298.39M | 171.44M | 130.23M | 89.51M | 16.55M | 57.49M | 13.89M | 28.23M | 9.09M | 2.21M |
Operating activities | ||||||||||
Net income | 71.41M | 83.07M | 39.48M | 74.98M | 31.87M | -34.00M | -18.41M | -18.07M | -20.23M | -15.50M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 32.88M | 1.23M | 192K | 885.31K | 297.72K | 37.97K | 45.68K | 43.40K | 34.46K | 26.57K |
Stock-based compensation expense | 14.25M | 7.90M | 6.07M | 6.26M | 3.82M | 0 | 2.40M | 1.83M | 1.58M | 777.96K |
| Deferred income tax benefit | 14.25M | 7.90M | 6.07M | 6.26M | 3.82M | 0 | 2.40M | 1.83M | 1.58M | 777.96K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -43.07M | -3.82M | -632K | 4.54M | -10.53M | 0 | 0 | 0 | 0 | 0 |
Inventories | -4.73M | 1.06M | -3.21M | -2.69M | -1.90M | -56.01K | 0 | 0 | 0 | 0 |
Accounts payable | 10.82M | 1.20M | -1.48M | 138.57K | 1.78M | 391.79K | 1.01M | -860.95K | -20.08K | 963.42K |
Cash generated by operating activities | 143.6M | 116.04M | 60.37M | 45.03M | 34.61M | -25.70M | -13.74M | -17.96M | -18.01M | -12.94M |
Investing activities | ||||||||||
Purchases Of Investments | -13.46M | -10M | -10M | -10M | -34.72M | -36.80M | -3.95K | -68.60K | -1.84K | -8.68M |
Investments In Property Plant And Equipment | -198.52M | -29K | -1.02M | -11.39K | -19.36K | -92.01K | 0 | -96.06K | -23.46K | -57.32K |
Acquisitions Net | 0 | 10M | 0 | 5M | -37.24M | 0 | 0 | 23.46K | 23.46K | 0 |
Cash generated by investing activities | -293.50M | 9.20M | -11.02M | -5.01M | 37.22M | -15.52M | -3.95K | 3.55M | -6.49K | -8.74M |
Financing activities | ||||||||||
Common Stock Issued | 2.79M | 0 | 4.09M | 758.13K | 1.11M | 0 | 53.77M | 0 | 34.87M | 26.72M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -982K | -6.90M | -12.24M | -56K | 0 | 0 | 0 | -11.26K | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | -10.85M | 1.69M | -8.14M | 701.93K | 1.11M | 293.11K | 57.35M | 68.98K | 37.15M | 28.56M |
Net Change In Cash | -160.75M | 126.95M | 41.20M | 40.72M | 72.95M | -40.93M | 43.60M | -14.34M | 19.13M | 6.88M |
Cash at end of period | 137.63M | 298.39M | 171.44M | 130.23M | 89.51M | 16.55M | 57.49M | 13.89M | 28.23M | 9.09M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |